ANNEXON INC (ANNX) Stock Price, Quote, News and Overview
NASDAQ:ANNX - Nasdaq - US03589W1027 - Common Stock - Currency: USD
ANNX Quote, Performance and Key Statistics
2.81
-0.02 (-0.71%)
The current stock price of ANNX is 2.81 USD. In the past month the price decreased by -33.73%. In the past year, price decreased by -46.48%.
ANNX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ANNX
Company Profile
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 84 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). The company is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). The company is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. The company has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.
Company Info
ANNEXON INC
1400 Sierra Point Parkway, Bldg C Suite 200
Brisbane California CALIFORNIA 94080 US
CEO: Douglas Love Esq.
Employees: 71
Company Website: https://annexonbio.com/
Investor Relations: https://ir.annexonbio.com/
Phone: 16508225500
ANNEXON INC / ANNX FAQ
What is the stock price of ANNEXON INC today?
The current stock price of ANNX is 2.81 USD. The price decreased by -0.71% in the last trading session.
What is the ticker symbol for ANNEXON INC stock?
The exchange symbol of ANNEXON INC is ANNX and it is listed on the Nasdaq exchange.
On which exchange is ANNX stock listed?
ANNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANNEXON INC stock?
14 analysts have analysed ANNX and the average price target is 15.47 USD. This implies a price increase of 450.53% is expected in the next year compared to the current price of 2.81. Check the ANNEXON INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANNEXON INC worth?
ANNEXON INC (ANNX) has a market capitalization of 299.52M USD. This makes ANNX a Micro Cap stock.
How many employees does ANNEXON INC have?
ANNEXON INC (ANNX) currently has 71 employees.
What are the support and resistance levels for ANNEXON INC (ANNX) stock?
ANNEXON INC (ANNX) has a resistance level at 4.09. Check the full technical report for a detailed analysis of ANNX support and resistance levels.
Should I buy ANNEXON INC (ANNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANNX, evaluating the profitability, health, valuation and growth aspects
- ANNEXON INC (ANNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANNEXON INC (ANNX) Sales and EPS estimates to see what analysts future expectations are.
- ANNEXON INC (ANNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANNEXON INC (ANNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANNEXON INC (ANNX) Stock Chart to make your own analysis
- ANNEXON INC (ANNX) Latest news and press-releases to stay up to date.
Does ANNEXON INC (ANNX) stock pay dividends?
ANNX does not pay a dividend.
When does ANNEXON INC (ANNX) report earnings?
ANNEXON INC (ANNX) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of ANNEXON INC (ANNX)?
ANNEXON INC (ANNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.05).
What is the Short Interest ratio of ANNEXON INC (ANNX) stock?
The outstanding short interest for ANNEXON INC (ANNX) is 10.23% of its float. Check the ownership tab for more information on the ANNX short interest.
ANNX Technical Analysis
ANNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANNX. While ANNX has a great health rating, there are worries on its profitability.
ANNX Financial Highlights
Over the last trailing twelve months ANNX reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS increased by 44.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.02% | ||
| ROE | -35.44% | ||
| Debt/Equity | 0 |
ANNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ANNX. The Buy consensus is the average rating of analysts ratings from 14 analysts.